32950 Autoantibody profiles of bullous immune-related cutaneous adverse events from immune checkpoint blockade may present with atypical or typical antibody serologies

Background: With immune checkpoint blockade (ICB) now standard of care in a multitude of cancer types, immune-related cutaneous adverse events (ircAEs) negatively impact quality of life and frequently lead to treatment interruptions. Autoimmune bullous ircAEs have been found to be overrepresented in patients treated with anti-PD1 antibodies when compared with matched controls. Furthermore, although cases of bullous ircAEs have been reported, no extensive characterization based on a larger cohort has been undertaken.